{
    "clinical_study": {
        "@rank": "78968", 
        "acronym": "A-C", 
        "arm_group": [
            {
                "arm_group_label": "postoperative chemotherapy,XELOX", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Preoperative Concurrent  Chemoradiotherapy", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "Stage I\uff1apreoperative therapy\n\n        -  Capecitabine plus oxaliplatin with  concurrent radiotherapy is superior to surgery\n           alone ; Stage II: Perioperative therapy\n\n        -  Perioperative  Capecitabine plus oxaliplatin with  Concurrent radiotherapy is superior\n           to adjuvant Capecitabine plus oxaliplatin alone;\n\n        -  A regimen of Capecitabine plus oxaliplatin(XELOX) improves survival among patients with\n           incurable locally advanced or metastatic adenocarcinoma of stomach and gastroesophageal\n           cancer . The investigators assessed whether the addition of a perioperative regimen of\n           XELOX regimen with  concurrent radiotherapy to adjuvant alone improves R0 resection\n           rate and survival among patients with curable locally advanced adenocarcinoma of\n           stomach and gastroesophageal cancer"
        }, 
        "brief_title": "Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Gastroesophageal Junction Adenocarcinoma", 
        "condition_browse": {
            "mesh_term": "Adenocarcinoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Disease must be clinically limited to the  esophagogastric junction, defined Type\u2161\n             Type\u2162(From the endoscopic point of view according to the AEG criteria)\n\n          2. Histologically confirmed primary adenocarcinoma\n\n          3. T2-4 N0-3 M0. T1 tumors are eligible if T1N1-3M0\uff0c\n\n          4. ECOG performance status \u22662\n\n        AEG is defined and described as tumors which have their center within 5cm proximal or\n        distal of the anatomical cardia.\n\n        The classification of AEG type I, type II and type III AEG type I: adenocarcinoma of the\n        distal esophagus,which usually arises from an area with specialized intestinal metaplasia\n        of the esophagus, i Barrett's esophagus, and may infiltrate the esophago-gastric junction\n        from above;\n\n          -  AEG type II: true carcinoma of the cardia, arising from the cardia epithelium or\n             short segments with intestinal metaplasia at the esophago-gastric junction;\n\n          -  AEG type III: subcardial gastric carcinoma, which infiltrates the esophago-gastric\n             junction and distal esophagus from below.\n\n        Exclusion Criteria:\n\n          1. Tis (in-situ carcinoma) and tumors determined to be TIN0 following endoscopy,\n             endoscopic ultrasound and CT scanning.\n\n          2. Patients with primary carcinomas of the esophagus.\n\n          3. Prior chest or upper abdomen radiotherapy, prior systemic chemotherapy within the\n             past 5 years, or prior esophageal or gastric surgery.\n\n          4. Patients with evidence of metastatic disease are not eligible.\n\n          5. Patients with a history of seizure disorder who are receiving phenytoin,\n             phenobarbital, or other antiepileptic medication.\n\n          6. Patients who cannot fully comprehend the therapeutic implications of the protocol or\n             comply with its requirements.\n\n          7. Patients with any medical or psychiatric condition or disease which, in the\n             investigator's judgment, would make the patient inappropriate for entry into this\n             study.\n\n          8. History of hypersensitivity to fluoropyrimidines, capecitabine, oxaliplatin or the\n             ingredients of this product -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "450", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 22, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01962246", 
            "org_study_id": "Alien-Craft"
        }, 
        "intervention": [
            {
                "arm_group_label": "postoperative chemotherapy,XELOX", 
                "description": "Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for eight cycles postoperation", 
                "intervention_name": "Oxaliplatin; Capecitabine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Xeloda", 
                    "Oxaliplatin"
                ]
            }, 
            {
                "arm_group_label": "Preoperative Concurrent  Chemoradiotherapy", 
                "description": "Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for two cycles preoperation , Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for six cycles postoperation Radiation: radiotherapy 50 Gy in 25 fractions (2Gy /day, 5 days/week,Monday through Friday, ) Other Name: XRT", 
                "intervention_name": "Oxaliplatin; Capecitabine; concurrent radiotherapy", 
                "intervention_type": "Other", 
                "other_name": [
                    "Xeloda", 
                    "Oxaliplatin", 
                    "XRT"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Oxaliplatin", 
                "Capecitabine", 
                "Fluorouracil"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Capecitabine", 
            "Oxaliplatin", 
            "Preoperative Concurrent  Chemoradiotherapy", 
            "Gastroesophageal Junction Adenocarcinoma"
        ], 
        "lastchanged_date": "October 10, 2013", 
        "location": {
            "contact": {
                "email": "zhaoqun516@yahoo.com.cn", 
                "last_name": "Qun Zhao, Doctor", 
                "phone": "+8613930162111"
            }, 
            "facility": {
                "address": {
                    "city": "Shijiazhuang", 
                    "country": "China", 
                    "state": "Hebei", 
                    "zip": "050011"
                }, 
                "name": "Department of General Surgery"
            }, 
            "investigator": {
                "last_name": "Qun Zhao, Dortor", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase II Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Concurrent Radiotherapy in Patients With Potentially Resectable Adenocarcinoma of Gastroesophageal Cancer", 
        "overall_official": {
            "affiliation": "Hebei Medical University", 
            "last_name": "Qun Zhao, Doctor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Disease-free survival(DFS)", 
            "safety_issue": "No", 
            "time_frame": "3 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01962246"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hebei Medical University", 
            "investigator_full_name": "Qun Zhao", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "R0-resection rate", 
                "safety_issue": "No", 
                "time_frame": "within 3 weeks after surgery"
            }, 
            {
                "measure": "Objective response rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "within 3 weeks after surgery"
            }, 
            {
                "measure": "Disease control rate (DCR)", 
                "safety_issue": "No", 
                "time_frame": "within 3 weeks after surgery"
            }, 
            {
                "measure": "Down-staging Rate", 
                "safety_issue": "No", 
                "time_frame": "within 3 weeks after surgery"
            }, 
            {
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "3years"
            }, 
            {
                "description": "Side effects during observation] Investigators graded all adverse events and toxic effects according to the National Cancer Institute's Common Toxicity Criteria, version 2.0. The number of Participants with adverse events will be recorded at each treatment visit.", 
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "3 year"
            }, 
            {
                "measure": "Death related to operation", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }
        ], 
        "source": "Hebei Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hebei Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}